Full-Time

Data Reviewer 3

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$84k - $104.8k/yr

Albany, NY, USA

In Person

On-site in Albany, NY; no remote option stated.

Bachelor's, Master's

Category
Biology & Biotech (1)

Get referred to Curia

See people who can refer or advise you

Requirements
  • Bachelor’s Degree in Chemistry or related field and a minimum of five years’ relevant industry experience; OR Master’s degree and three years’ relevant experience
  • Must pass a background check
  • Must pass a drug screen
  • May be required to pass Occupational Health Screening
Responsibilities
  • Responsible for technical data review of the raw data generated for various compendial testing (such as USP/NF, EP, JP, etc.) as well as Curia In-house and client methodologies for various client projects to ensure data accuracy and integrity
  • Must have working knowledge and understanding of various analytical instrumentation including but not limited to Gas Chromatography (GC), High-performance liquid chromatography (HPLC/UHPLC), ICP-MS, Infrared spectroscopy (IR), Differential scanning calorimeter (DSC), UV-Vis, Karl-Fischer auto titrator, Optical rotation, Dissolution, etc.
  • Trend stability data to ensure consistency with historical timepoints and no unexpected results
  • Verify calculations associated with Stability samples/Reference standards/Raw Materials/Intermediates testing are correctly done
  • Format and review Stability summary tables, Stability Protocols for accuracy and compliance with current Curia formats
  • Enter data into Stability summary tables. Perform tracking and trending of data as requested. Compile data and provide data summaries to management
  • Collaborate with lab personnel for data review per cGMP compliance, data integrity
  • Perform electronic review and signatures while reviewing electronic data
  • Verify for traceability of samples, standards, reagents, instruments etc.
  • Verify the usage logbook, calibration of instruments and shelf life of standards and reagents used are current and GDP procedures are followed
  • Ensure the testing data received from external labs are reviewed per site procedures
  • Make sure all tests are per cGMP compliance and in compliance with the company’s standard operating procedures
  • Provide support on QA initiatives (Investigations, change controls etc.) when necessary
  • Review and approve test methods, SOPs, forms, and other documents as necessary
  • Support supervisors in OOS Investigations and complete CAPA requirements
  • Participate in customer technical discussions for analytical issues
  • Interact with outside departments including attending meetings, providing updates, etc.
  • Coordinate testing performed at contract testing labs for stability samples etc.
  • Provide training to new hires as needed. Attend internal and external training on related subjects, cGMP compliance and data integrity, new techniques and procedures
  • Provide guidance to lower level Data Reviewers as needed
Desired Qualifications
  • Experience working in cGMP or GLP pharmaceutical industry environment

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Albuquerque’s $200 million expansion adds commercial drug-product capacity during 2025-2026.
  • Glasgow’s upgrade reaches early 2027, expanding batches to 20,000 vials.
  • March 2025 refinancing and July 2026 recapitalization inject capital for near-term execution.

What critics are saying

  • Apollo-led recapitalization on July 8, 2026 signals strained leverage and lender control.
  • Curia will close Burlington by June 1, 2026, cutting 81 jobs and shrinking capacity.
  • Octus reported June 2, 2026 out-of-court restructuring talks; a failed process risks insolvency.

What makes Curia unique

  • Curia spans discovery through commercial fill-finish across 20+ sites, rare among CDMOs.
  • Glasgow and Albuquerque expansions deepen sterile injectables capacity, including Annex 1 isolator lines.
  • Hopkinton CLD upgrades deliver sixfold higher titers, strengthening biologics process-development economics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.